How to Introduce Carotid Angioplasty without Compromising Patient Safety  by Balzer, Jörn O.
Eur J Vasc Endovasc Surg (2008) 36, 138e144CAROTID MASTERCLASS
How to Introduce Carotid Angioplasty without
Compromising Patient Safety*Jo¨rn O. Balzer*Department of Radiology and Nuclear medicine, Catholic Clinic Mainz, An der Goldgrube 11, 55131 Mainz, Germany
Submitted 15 May 2008; accepted 15 May 2008
Available online 24 June 2008KEYWORDS
Stroke;
Carotid artery;
Angioplasty;
Stent;
Carotid endarterectomy* One of a series of articles edited b
* Tel.: þ49 6131 575 1700; fax: þ49
E-mail address: balzerjo@t-online.
1078-5884/$34 ª 2008 European Socie
doi:10.1016/j.ejvs.2008.05.002Abstract Carotid angioplasty with stenting (CAS) is increasingly being used in the treatment
of extracranial carotid disease and numerous studies have demonstrated its feasibility.
However, the exact role of CAS in the treatment of carotid stenosis and its long-term efficacy
has not been defined. The assessment of the patient’s medical condition, the exact identifica-
tion of vessel anatomy as well as anomalies of the aortic arch and the cervicocerebral
circulation is required for successful and safe performance of CAS. New CAS practitioners
would be advised to start their experience in patients with predominantly easier anatomical
situation as well as plaque configuration.
The appropriate selection of interventional techniques as well as vascular access for CAS is
dependent on the anatomy of the aortic arch and of the CCA proximal to the target lesion.
Usually a retrograde femoral artery approach to access the CCA is preferred. In order to treat
a patient safely with carotid artery stenting, it essential for interventionalists to appropriately
chose a patient suited for endovascular therapy, to identify possible sources of complications
prior to the interventional procedure as well as to know the key points for a successful carotid
artery intervention. An interdisciplinary evidence-based approach will facilitate the choice of
optimal intervention for each patient. Finally, trainee programs for physicians starting with
CAS as well as facility certification are absolutely mandatory to ensure high success rates as
well as low complication rates.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
In 2007 stroke was identified as the third leading cause of
death (164,000 deaths/year) in the US (after heart diseasey Prof. A. Ross Naylor, Leicester,
6131 575 1709.
de
ty for Vascular Surgery. Publisheand cancer and approximately 1 million stroke-related
events occur each year. According to Bates et al. these
latter events can be subdivided into 500,000 new strokes,
200,000 recurrent strokes, and 240,000 transient ischemicUK.
d by Elsevier Ltd. All rights reserved.
Table 1 Common increased surgical risk features
[modified from 24]
General criteria Anatomic criteria
 Unstable angina
 Myocardial infarction
within 30 days
 NYHA class 3 or 4
congestive heart failure
 Multivessel coronary
artery disease
(non-revascularized)
 Reduced left ventricular
ejection fraction (<30%)
 Cardiac or vascular
surgery required within
30 days
 Chronic obstructive lung
disease (FEV1< 30% of
predicted)
 Age greater than 75 years
 Lesions higher than C2 or
lower than C6
 Tandem carotid lesions
requiring treatment
 Restenosis following
ipsilateral CEA
 Ipsilateral radical neck
dissection or irradiation
 Tracheostomy
 Bilateral severe carotid
artery stenosis
 Contralateral carotid
artery occlusion
 Contralateral CEA
resulting in cranial
nerve injury
NYHA: New York Heart Association; FEV1: Forced expiratory
volume in one second; CEA: Carotid endarterectomy.
Introduce Carotid Angioplasty 139attacks (TIAs). Overall, it is likely that carotid artery
disease suitable for revascularization accounts for 5% to
12% of new strokes.1
Carotid angioplasty with stenting (CAS) is increasingly
being used in the treatment of extracranial carotid disease
and numerous studies have demonstrated its feasibility. In
order to replace carotid endarterectomy (CEA) as the
standard treatment for carotid artery disease, however,
CAS has to be shown to be at least as safe and effective as
surgery. However, the exact role of CAS in the treatment of
carotid stenosis and its long-term efficacy has not yet been
defined.2e16 Part of the controversy arises from confusion
about which physicians should treat carotid artery disease.
With the introduction of CAS, a broad variety of ‘‘vascular
specialists’’ have established endovascular treatment of
carotid artery disease into their routine practice. This has
occurred in parallel with important innovations in the
device (stent, protection device), technical refinements
and a better knowledge of patient selection.17,18
With the introduction of CAS, vascular surgeons have
been challenged to change their attitude regarding the
management of severe carotid artery disease.17 The two
most referenced trials in the current clinical decision-
making process for carotid stenosis are the North American
Symptomatic Carotid Endarterectomy Trial (NASCET) and
the Asymptomatic Carotid Atherosclerosis Study (ACAS).
Both concluded that there was a clear benefit for CEA in pa-
tients with symptomatic and asymptomatic carotid occlu-
sive disease.19,20 These landmark trials typically included
patients who were considered to be at low or intermediate
risk of perioperative events. Patients who were considered
‘high risk for surgery’ were excluded. This became evident
when published death rates were found to be significantly
higher in post-NASCET and ACAS era of treating patients,
even though these audits were undertaken in the same
hospitals where NASCET and ACAS had recruited patients.22
Thirty day stroke and death rates of 3 and 6% in asymptom-
atic and symptomatic patients, respectively, are now
considered the benchmark for acceptable results for CEA
based on the results of these early trials. It is therefore ex-
pected that the outcome of CAS should achieve a similar
standard.21,23 In current clinical practice, CAS has emerged
as a viable alternative for patients who are deemed at ‘high
risk for surgery’ or ‘poor’ candidates for CEA, which is now
considered the standard of care.24 Several trials have sug-
gested equivalent results for CAS and CEA.24e28
While a number of important issues still need to be
resolved, it is likely that an increasing number of clinicians
will want to learn how to perform CAS. This paper will
review how this can be achieved without compromising
patient safety.Patient Selection
Since the early and mid 1990s, CAS has emerged as an
alternative to surgery in patients who are considered ‘high
surgical risk’. Over time, the definition of increased surgical
risk has been established into two main categories. The first
(general) high-risk category includes; patients with medical
co morbidities such as New York Heart Association class 3 or
4 congestive heart failure, reduced left ventricular ejectionfraction (<30%), unstable angina, multivessel coronary
artery disease (non-revascularized), myocardial infarction
within 30 days, cardiac or vascular surgery required within
30 days, chronic obstructive lung disease with forced
expiratory volume in one second of <30% predicted, or
age older than 75 years.24 The second (anatomical) high-
risk category includes; carotid lesions located proximally
or distally beyond conventional surgical access (lower
than the sixth or higher than second cervical vertebral
bodies), tandem carotid lesions requiring treatment, a his-
tory of ipsilateral CEA or radical neck dissection, neck
irradiation, tracheostomy, bilateral severe carotid artery
stenosis requiring treatment, contralateral carotid occlu-
sion, or contralateral CEA which has already caused
a cranial nerve injury24 (Table 1).
In addition to the assessment of the patient’s medical
condition, the exact identification of vessel anatomy as
well as anomalies of the aortic arch and the cervicocerebral
circulation is required for successful and safe performance
of CAS (Table 2). Arch elongation and calcification and ves-
sel tortuosity are all features that generally increase the
difficulty of CAS and thus increase the likelihood of encoun-
tering procedural complications. Although more common in
the older patient, these characteristics may be found in
patients of any age and may be considered as risk factors
for perioperative stroke with CAS.29 It is important to rec-
ognize the type of aortic arch and the configuration of
the great vessels in each patient, since these anatomic
features influence procedure complexity.
There are three types of aortic arch, based on the
relationship of the innominate artery to the aortic
arch.1,30,31 The type I aortic arch is characterized by the
origin of all 3 great vessels being in the same horizontal
plane as the outer curvature of the aortic arch. In the
type II aortic arch, the innominate artery originates
between the horizontal plane of the outer and inner curva-
tures of the aortic arch. In the type III aortic arch, the
innominate artery originates below the horizontal plane
Table 2 Anatomic and clinical evaluation of favorable and
unfavorable arterial characteristics for CAS [modified from
29]
Favorable Unfavorable
Arch elongation Vessel origins off
top of the arch
(type I)
Origin from ascending
or between greater
and lesser curvatures
(type III), severe
posterior rotation
Arch calcification No or minimal Luminal irregularity
or diffuse
calcification
Origin stenosis <50% >50%
Carotid tortuosity <30 angularity >30 angularity
Lesion stenosis <99% >99% or occlusion
Lesion
calcification
No or trace
shadowing
Severe calcification
Thrombus None Presence of fresh
thrombus
Lesion length 0e5 mm >5 mm
Aneurysm None Ipsilateral
intracranial
aneurysms >5 mm
Age <80 years >80 years
Cerebral reserve Sufficient Reduced (e.g. prior
stroke, dementia)
CCA: Common carotid artery; ICA: internal carotid artery.
Figure 2 IADSA showing a type II aortic arch. The innomi-
nate artery originates between the horizontal planes of the
outer and inner curvatures of the aortic arch. Additionally
this patient presented with a stenosis of the left subclavian
artery (white arrow).
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the origin of the target artery (i.e. type II or III aortic arch),
the greater the difficulty in gaining access to the carotid
artery (Figs. 1e3). Accordingly, new CAS practitioners
would be advised to start their experience in patients
with predominantly type 1 arches, because the major diffi-
culty lies in the appropriate placement of the guiding
catheter or sheath without causing distal emboli or dissec-
tion. In either arch, the placement of a stiff guidewire inFigure 1 CE-MRA of a type I aortic arch with all 3 great ves-
sels in the same horizontal plane as the outer curvature of the
aortic arch. In addition, an anatomical variation in the origin of
the left vertebral artery was detected (white arrow) as well as
a stenosis of the left subclavian artery (yellow arrow).the ipsilateral ECA is necessary in order to prevent distal
embolisation through guidewire manipulation at the level
of the carotid stenosis.
In addition to the type of arch, the configuration of the
great vessels is also important when planning any CAS
procedure. In the usual configuration, the innominateFigure 3 IADSA of the aortic arch with depiction of a type III
aortic arch where the innominate artery originates below the
horizontal plane of the inner curvature of the aortic arch.
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subclavian artery have separate origins from the arch. Two
common anomalies are encountered in clinical practice,
both of which have been erroneously termed ‘bovine
arches’. In fact, neither of these variants bears any
resemblance to the actual anatomy seen in cattle! The
first variant is where there is a common origin to the
innominate artery and the left CCA. The second common
anomaly is where the left CCA arises as a branch of the
innominate artery. Both of these conditions can cause
access difficulties for less experienced CAS practitioners
and this should be considered during case selection. Other
anatomical variations can occur more distally in the carotid
circulation. The distal CCA usually bifurcates into the
internal carotid artery (ICA) and the external carotid artery
(ECA) at the level of the thyroid cartilage, but an anoma-
lous bifurcation may occur anywhere within 5 cm above or
below this level, and there are many variations in the
position of the ICA relative to the ECA. There is also consid-
erable variation in length and tortuosity of the ICA, with up
to 35% of individuals having some form of coiling or kinking
of the ICA, particularly in the older patient.
Even with increasing experience of performing CAS, it is
important to continue to remember those factors that
make the procedure more difficult or even hazardous. In
the elderly patient, the increased susceptibility of the brain
to emboli, hypo- or hyperperfusion increases the risk of
a suffering a neurologic event after CAS.27 At the time of
writing, relatively little reliable information exits regarding
which anatomical factors predispose individual elderly
patients to increased procedural risk (there is still no known
association between plaque calcification and age32), but
the less experienced CAS practitioner might be best advised
to develop their practice on a younger cohort of patients
before expanding this into an older patient population.
Technique of Carotid Artery Stenting
Historical perspective
Balloon angioplasty of the first carotid artery stenosis was
performed in 1979; the first cerebral protection systems
were used in the early where a distal balloon occlusion
system as used to reduce embolic complications.4,11,15,33
The first balloon-expandable stent was deployed in a carotid
artery in 1989, however these stents were prone to com-
pression and major adverse events occurred in more than
10% of patients at 30 days follow-up.34,35 The introduction
of the self-expanding Wallstent, supplemented later by
self-expanding nitinol stents solved these problems.10,18
However, the risk of embolic stroke was themain concern
that limited early carotid artery PTA. Initial strategies
focused on neurological rescue interventions, but then
shifted to neurological protection, leading to the develop-
ment of dedicated embolic protection devices (EPD) to
capture and remove embolic debris that were generated
during the course of the interventional procedure. Notwith-
standing these important technological innovations, that
certainly improved outcomes, CAS still careful training of
the operator and wide experience in endovascular pro-
cedures in order to achieve low complications rates.Technique
From a clinical standpoint, the main goal of carotid
revascularization is to prevent stroke. Since most strokes
follow thromboembolism, most interventionalists feel that
it is more important to reduce the overall risk of embolisa-
tion than completely eliminate the carotid stenosis. From
a technical point of view, the main aims of CAS are to
enlarge the lumen as well as cover the lesion by placement
of a stent. This requires careful imaging of the carotid
artery and intracranial circulation before and after CAS.
Generally, an angiographic examination of the target lesion
in two projections is required, as well as an angiographic
examination of the intracranial circulation in anteroposte-
rior and lateral projections.
All patients should be pretreated with acetylsalicylic
acid (ASA) at a mean dosage of 100 mg/day and with clopi-
dogrel at a mean dosage of 75 mg/day for at least 6 days
prior to intervention. Clopidogrel (75 mg/day) should then
be continued for at least one month after the interven-
tional procedure. Thereafter, mono antiplatelet therapy
(aspirin or clopidogrel) should be continued on a life-time
basis.
Carotid access
Appropriate selection of interventional material for CAS is
dependent on the anatomy of the aortic arch and of the
CCA proximal to the target lesion. Usually a retrograde
femoral artery approach to access the CCA is preferred.
Additionally, a right brachial or radial access is required,
particularly in cases involving an anomalous left CCA
arising from the proximal innominate artery or in cases
where transfemoral access is not possible due to severe
inflow occlusive disease. Access to the CCA is achieved by
using either a guiding catheter or an interventional
sheath.
The choice of technique is largely operator dependent,
although there are several anatomic factors that might
favor one technique over another. When treating patients
with a simple arch and carotid anatomy, a 6-F interven-
tional sheath or an 8-F guiding catheter can be employed.
The tip is usually positioned in the distal CCA, a few
centimeters below the carotid bifurcation. In cases which
require a more aggressive guiding catheter shape, the tip of
the guide is usually positioned in the proximal (intratho-
racic) segment of the CCA, although this generally provides
less support for the procedure. Careful placement of the tip
of guiding catheter or interventional sheath will help
prevent spasm, thrombosis, or dissection. Strict manage-
ment of catheter flushing and elimination of air is essential
to avoid periprocedural emboli. In addition, in order to
minimize embolisation, the target lesion should be sub-
jected to as little manipulation as possible.
Carotid artery angioplasty and stenting
After access has been achieved 5000e10000 I.U. of intra-
arterial heparin should be administered with the aim of
achieving an activated clotting time (ACT) of 250 to 300 s.
The next step involves placement of the EPD. The choice
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anatomical as well as haemodynamic factors and predilata-
tion may be necessary in cases where the passage of the
lesion with a distal EPD is not possible and proximal protec-
tion is not indicated. After placement of the EPD, PTA with
undersized balloons (3 to 4 mm in diameter and 15 to
40 mm in length; a balloon to ICA ratio of 0.5 to 0.6) are
selected to allow passage of the stent delivery system, if
needed. This is especially important in severe stenosis since
removal of the stent delivery catheter could become impos-
sible otherwise. Additionally, undersized angioplasty
balloons (4.5 to 6 mm in diameter and 15 to 30 mm in
length) are used to expand the stent after deployment.
The goal of CAS is not to eliminate the stenosis altogether,
but to reduce the risk of thromboembolism. Accordingly,
a moderate residual stenosis (30% to 40%) is acceptable.
Nitinol self-expanding stents show a tendency to continue
to expand within the lumen after the procedure, and it is
possible that a moderate residual stenosis immediately
after intervention may remodel into a milder residual
stenosis several few months later. The number of balloon
inflations should be kept to the minimum as vasovagal or
vasodepressor reactions may increase complications. Most
interventionists recommend administering Atropine (0.5
to 1 mg) to the majority of patients just before the post-
stenting PTA phase to reduce the risk of bradycardia and
hypotension. Atropine should not be administered to
patients with tachycardia and uncontrolled systemic
hypertension.
Choosing the right stent
The choice of stent (balloon vs self expandable) is relatively
straightforward. Balloon expandable stents are generally
used for intrathoracic lesions (eg at the origin of the CCA),
while for the cervical portion of the distal CCA or proximal
ICA, self-expanding stents are recommended. Nitinol self-
expanding stents are preferred by most operators over
stainless steel stents because of better conformability, lack
of shortening, and predictable deployment. However, early
and late published results appear to be similar, regardless
of stent design. All self-expanding carotid stents have
delivery systems that are compatible with 0.014-inch
guidewires, which is the most common platform for de-
livering distal EPDs. Many nitinol stents are now available in
tapered designs so as to conform to the tapered transition
from the larger CCA (8 to 10 mm in diameter) to the smaller
ICA (5 to 7 mm in diameter), although there are no data to
suggest better outcomes compared with non-tapered de-
signs. Stent lengths (most commonly 30e40 mm) are usually
chosen to achieve complete lesion coverage (normal-to-
normal from the distal CCA to the proximal ICA). There is
still a lot of debate about whether ‘open’ or ‘closed’ stent
designs are optimal. Although open cell stents allow
a higher degree of stent conformability, it does permit
more extrusion of plaque material through the stent inter-
stices. Conversely, closed cell stents offer very good plaque
coverage at the expense of greater rigidity and lower
conformability. So called ‘hybrid’ stents (a sandwich of
open cell:closed cell:open cell components) could allow
optimal plaque coverage with greater conformability.Discussion
The management of carotid atherosclerosis remains one of
the most controversial areas of vascular practice, despite
attracting more randomised trials than any other problem
in peripheral artery disease. Presently the most hotly
debated topic is carotid stenting. Over the last decade
there has been an increasing shift towards the endovascular
treatment of most vascular beds. In many countries this
also applies to the treatment of carotid stenosis.
Luebke and colleagues presented a meta-analysis of
trials comparing CAS and CEA for the treatment of carotid
stenosis. The main findings were that CAS was associated
with increased risk of perioperative stroke, OR 1.50 (95% CI:
1.05-2.16), but a reduced risk of cranial nerve injury, OR
0.15 (95% CI: 0.09-0.26).2 No difference in outcome at one
year was found, however, few of the studies analyzed have
as yet reported at this time point. Based on these findings
the authors concluded that CEA remains the ‘‘gold stan-
dard’’ in the treatment of carotid stenosis and CAS should
only be carried out as part of an on-going randomized trial.
It should be noted that the authors finding of a worse peri-
operative outcome in patients randomised to CAS only held
for a fixed effect model and was not demonstrated with the
statistically more conservative random effect model.2
The randomized trials of CAS and CEA have not had the
same impact as the ‘‘surgery versus best medical therapy’’
trials of the 1980s, failing to show superiority for either
modality. Moreover, several of these trials have raised
concerns about the procedural risk of CAS, and even the
greatest protagonists of CAS would accept that some
elements of case selection are absolutely essential in order
to achieve clinically acceptable rates of technical success
and low rates of stroke and death. With the available data
for symptomatic patients, there is little to recommend the
routine use of CAS, and patients should continue to be
randomized to the ongoing randomized trials. Furthermore,
there should be a concerted effort to concentrate
resources on treating symptomatic carotid disease as an
emergency, with specialized units providing a multidisci-
plinary team approach, offering expedient imaging, throm-
bolysis, and appropriate intervention. Loftus et al. stated,
that there may be a role for CAS in asymptomatic disease,
however as with symptomatic disease, there are no trial
data to recommend routine intervention in asymptomatic
individuals. Ongoing randomized trials may provide clearer
guidance in this domain, but in order to demonstrate
equivalence for CAS, each individual center will need to
demonstrate a 3% periprocedural stroke and death rate.
Even with excellent technical results, the clinical benefit
will be small for asymptomatic patients.36
However, CAS is now considered a favorable alternative
to CEA in ‘high-risk’ patients. FDA approved carotid stent
and embolic protection systems are currently available.
Many interventionists predict that CAS will become at least
an equal alternative to CEA in the general patient popula-
tion, pending the results of multiple ongoing prospective
randomized trials.24
This author agrees with the guidelines established by the
AHA/ASA (American Stroke Association) and these provide
a useful ‘starting point’ for those interested in developing
Introduce Carotid Angioplasty 143a CAS practice. Symptomatic patients who would otherwise
have a low operative risk with either moderate (50%e69%)
or severe (70%e99%) stenosis are recommended to undergo
CEA, whereas patients who are symptomatic with severe
stenosis (>70%) and who are ‘high risk for CEA’ are
recommended to undergo CAS.37 What should the ‘less
experienced’ CAS practitioner do about asymptomatic
patients? For the asymptomatic patient who is likely to
face a low operative risk, two areas of controversy exist.
First, is intervention really needed in these patients and
second, if an intervention is warranted, what should be
the threshold stenosis for intervening?.1 A number of rand-
omised trials are now recruiting ‘standard risk’ asymptom-
atic patients and this is the ideal forum to evaluate the
respective roles of surgery, CAS and ‘best medical therapy’.
Although CAS would seem to be an appropriate intervention
for patients who would otherwise face a ‘high operative
risk’, no level I data are currently available to support
this type of intervention. In this situation, less experienced
CAS practitioners should probably avoid becoming
embroiled in this controversy!Conclusion
Carotid artery stenting is a validated, approved, and
possibly superior treatment alternative for selected
patients with carotid artery stenosis. Improved device
technology, operator experience, and adjunctive pharma-
cotherapy have led to significant improvement in carotid
artery stenting outcomes over the past years. The clinical
trials published so far demonstrate the advancement of
CAS and the likely future in which CAS will become the
treatment of choice for carotid artery stenosis, whereas
CEA will be reserved for patients with anatomic and
clinical contraindications to CAS.38e40 This is also re-
flected by the creation of CAS reimbursement policies
by the Center for Medicare and Medicaid Services (CMS)
(Table 3), training and credentialing guidelines by multi-
ple societies, creation of reimbursement codes, and the
increasing number of CAS procedures performed. Notwith-
standing this, patient safety remains the primary goal of
physicians involved in the management of patients with
carotid artery stenosis and an interdisciplinary evidence-
based approach will facilitate the choice of optimal inter-
vention for each patient. Finally, trainee programs for
physicians starting with CAS as well as facility certification
are absolutely mandatory to ensure high success rates as
well as low complication rates.41e43Table 3 Criteria for CAS according to the Center for Medi-
care and Medicaid Services (CMS) and FDA decision40,41
CMS
coverage
criteria
FDA-labeled
criteria
High surgical risk YES YES
Symptomatic, Stenosis 70% YES NO
Symptomatic, Stenosis 50e70% NO NO
Asymptomatic, Stenosis 80% YES YES
embolic protection device required YES YESReferences
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